metres manufactures Tablets, Liquid Orals and Injectables.On 19 February 2016, Cadila Healthcare announced that it has received approval from the USFDA to market Doxycycline Capsules USP, 50 mg ...

Otulfi will be available in the U.S. in the following presentations: a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled ... Otulfi is also indicated for pediatric patients ≥6 years of age with moderate ...

Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim ...

Is the Neulasta Market Poised for Significant Growth? The Neulasta market has experienced considerable expansion in recent years, with a strong historic compound annual growth rate (HCAGR). .The ...

Piscataway, N.J., United States: Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection ...

PISCATAWAY, N.J. — Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial ...

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...